Redeye notes an exceptionally strong Q1 with record sales.
Redeye provides an initial comment on Catella’s Q1 2025 report.
Redeye updates its view on Xbrane following a stronger-than-expected Q1 report, with both revenue an...
Redeye updates on W5 Solutions following a softer than expected Q1-report.
Sales 9% below us, but partly temporary; orders grew 61% Mixed outlook, reiterates guidance, but cit...
Redeye updates its estimates after reviewing Tessin's Q1 report, which came in below expectations.
Redeye provides an update following Corline’s Q1 2025 report.
Redeye noted that BeammWave's Q1 2025 report significantly exceeded expectations, primarily due to r...
Redeye notes that Sivers’ Q1 2025 report was strong, with another quarter of record net sales reachi...
Redeye returns with positive estimate adjustments following GomSpace’s trading update that beat our ...
Fiskars announced yesterday evening that the CEO, Nathalie Ahlström will step down with imminent eff...
Redeye retains its Base Case and makes minor forecast adjustments following the full Q1 report, with...
Strong Q1 sales of SEK 57m, +49% y-o-y '25e-'27e sales and EBIT up 5-6% and 9%, respectively Growth ...
STENOCARE A/S (STENOCARE or the “Company”) published on May 8th the Company’s Q1-report for 2025.
Encouraging results, even if it was low season We raise our EBITA estimates 2-3% on '25e-'27e Svensk...
AcuCort (”AcuCort” eller ”Bolaget”) har publicerat Bolagets delårsrapport för det första kvartalet 2...
Redeye provides an initial take following the release of Corline’s Q1 2025 report.
Redeye's provides its initial take on Xbrane's Q1 report which confirmed a stronger than anticipated...
Redeye provides a brief comment on Paxman’s announcement to complete the offer for Dignitana.
Redeye notes that Paxman completes the offer to Dignitana.
